BACKGROUND: Genetic association studies, including a large meta-analysis, report association of regulator of G protein signaling 4 (RGS4) with schizophrenia in the context of heterogeneity. The central role of RGS4 in regulating signaling via Gi/o coupled neurotransmitter receptors led us to hypothesize that there may be RGS4 genotypes predictive of specific disease phenotypes and antipsychotic treatment responses. METHODS: Subjects were 678 individuals with schizophrenia who participated in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Among the 678 subjects, the inferred ancestries were 198 (29%) "Africa only," 397 (59%) "Europe only," and 83 (12%) "Other." Eight single nucleotide polymorphisms (SNPs) spanning RGS4 were genotyped. Multiple linear regression was used to analyze association of RGS4 markers with Positive and Negative Symptoms Scale (PANSS) scores at baseline and throughout antipsychotic treatment. RESULTS: Two consecutive markers within RGS4, rs2661319 and rs2842030, were associated with more severe baseline PANSS total score. Treatment with perphenazine was more effective than treatment with quetiapine (p = .010) or ziprasidone (p = .002) in individuals of inferred African ancestry and homozygous for the rs951439 C allele. CONCLUSIONS: RGS4 genotypes predicted both the severity of baseline symptoms and relative responsiveness to antipsychotic treatment. Although these analyses are exploratory and replication is required, these data provide support for RGS4 in schizophrenia pathogenesis and suggest a functional role for RGS4 in differential antipsychotic treatment efficacy of schizophrenia.
BACKGROUND: Genetic association studies, including a large meta-analysis, report association of regulator of G protein signaling 4 (RGS4) with schizophrenia in the context of heterogeneity. The central role of RGS4 in regulating signaling via Gi/o coupled neurotransmitter receptors led us to hypothesize that there may be RGS4 genotypes predictive of specific disease phenotypes and antipsychotic treatment responses. METHODS: Subjects were 678 individuals with schizophrenia who participated in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Among the 678 subjects, the inferred ancestries were 198 (29%) "Africa only," 397 (59%) "Europe only," and 83 (12%) "Other." Eight single nucleotide polymorphisms (SNPs) spanning RGS4 were genotyped. Multiple linear regression was used to analyze association of RGS4 markers with Positive and Negative Symptoms Scale (PANSS) scores at baseline and throughout antipsychotic treatment. RESULTS: Two consecutive markers within RGS4, rs2661319 and rs2842030, were associated with more severe baseline PANSS total score. Treatment with perphenazine was more effective than treatment with quetiapine (p = .010) or ziprasidone (p = .002) in individuals of inferred African ancestry and homozygous for the rs951439 C allele. CONCLUSIONS:RGS4 genotypes predicted both the severity of baseline symptoms and relative responsiveness to antipsychotic treatment. Although these analyses are exploratory and replication is required, these data provide support for RGS4 in schizophrenia pathogenesis and suggest a functional role for RGS4 in differential antipsychotic treatment efficacy of schizophrenia.
Authors: Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland Journal: Am J Hum Genet Date: 2001-12-27 Impact factor: 11.025
Authors: Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler Journal: Science Date: 2002-05-23 Impact factor: 47.728
Authors: Jun Ding; Jaime N Guzman; Tatiana Tkatch; Songhai Chen; Joshua A Goldberg; Philip J Ebert; Pat Levitt; Charles J Wilson; Heidi E Hamm; D James Surmeier Journal: Nat Neurosci Date: 2006-05-14 Impact factor: 24.884
Authors: Kodavali V Chowdari; Karoly Mirnics; Prachi Semwal; Joel Wood; Elizabeth Lawrence; Triptish Bhatia; Smita N Deshpande; Thelma B K; Robert E Ferrell; Frank A Middleton; Bernie Devlin; Pat Levitt; David A Lewis; Vishwajit L Nimgaonkar Journal: Hum Mol Genet Date: 2002-06-01 Impact factor: 6.150
Authors: Xiangning Chen; Cynthia Dunham; Seth Kendler; Xu Wang; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2004-08-15 Impact factor: 3.568
Authors: Julian Little; Linda Bradley; Molly S Bray; Mindy Clyne; Janice Dorman; Darrell L Ellsworth; James Hanson; Muin Khoury; Joseph Lau; Thomas R O'Brien; Nat Rothman; Donna Stroup; Emanuela Taioli; Duncan Thomas; Harri Vainio; Sholom Wacholder; Clarice Weinberg Journal: Am J Epidemiol Date: 2002-08-15 Impact factor: 4.897
Authors: Anna C Need; Richard S E Keefe; Dongliang Ge; Iris Grossman; Sam Dickson; Joseph P McEvoy; David B Goldstein Journal: Eur J Hum Genet Date: 2009-01-21 Impact factor: 4.246
Authors: Rebecca N Jerome; Jill M Pulley; Nila A Sathe; Shanthi Krishnaswami; Alyssa B Dickerson; Katherine J Worley; Consuelo H Wilkins Journal: Ethn Dis Date: 2020-04-02 Impact factor: 1.847
Authors: J L McClay; D E Adkins; K Aberg; S Stroup; D O Perkins; V I Vladimirov; J A Lieberman; P F Sullivan; E J C G van den Oord Journal: Mol Psychiatry Date: 2009-09-01 Impact factor: 15.992
Authors: Konasale M Prasad; Laura Almasy; Ruben C Gur; Raquel E Gur; Michael Pogue-Geile; Kodavali V Chowdari; Michael E Talkowski; Vishwajit L Nimgaonkar Journal: Schizophr Bull Date: 2009-03-12 Impact factor: 9.306